O Shaughnessy Asset Management LLC Sells 3,257 Shares of Tenet Healthcare Corporation $THC

O Shaughnessy Asset Management LLC cut its stake in Tenet Healthcare Corporation (NYSE:THC) by 7.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 37,878 shares of the company’s stock after selling 3,257 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Tenet Healthcare were worth $7,527,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in THC. Caption Management LLC bought a new position in Tenet Healthcare in the 3rd quarter valued at $5,650,000. Hillsdale Investment Management Inc. grew its stake in Tenet Healthcare by 31.0% in the 3rd quarter. Hillsdale Investment Management Inc. now owns 22,800 shares of the company’s stock valued at $4,629,000 after purchasing an additional 5,400 shares during the period. Eminence Capital LP bought a new position in shares of Tenet Healthcare during the 3rd quarter worth $225,263,000. GenTrust LLC bought a new position in shares of Tenet Healthcare during the 3rd quarter worth $895,000. Finally, Sirios Capital Management L P grew its stake in shares of Tenet Healthcare by 100.9% during the 3rd quarter. Sirios Capital Management L P now owns 71,566 shares of the company’s stock worth $14,531,000 after acquiring an additional 35,947 shares during the period. 95.44% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

THC has been the subject of a number of recent analyst reports. Mizuho lifted their target price on Tenet Healthcare from $235.00 to $265.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Truist Financial raised their price objective on Tenet Healthcare from $240.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Tenet Healthcare in a report on Wednesday, March 4th. Morgan Stanley set a $254.00 target price on shares of Tenet Healthcare in a report on Friday, May 1st. Finally, UBS Group boosted their target price on Tenet Healthcare from $260.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Eighteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $244.16.

Tenet Healthcare Trading Down 1.2%

NYSE:THC opened at $164.44 on Thursday. The business has a fifty day moving average price of $184.55 and a 200-day moving average price of $200.25. The firm has a market capitalization of $14.16 billion, a price-to-earnings ratio of 8.55, a price-to-earnings-growth ratio of 1.37 and a beta of 1.28. The company has a debt-to-equity ratio of 1.96, a current ratio of 1.36 and a quick ratio of 1.30. Tenet Healthcare Corporation has a one year low of $146.60 and a one year high of $247.21.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings data on Thursday, April 30th. The company reported $4.82 EPS for the quarter, beating the consensus estimate of $4.21 by $0.61. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. The firm had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.39 billion. During the same period last year, the firm earned $4.36 EPS. The company’s revenue was up 2.6% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. Sell-side analysts forecast that Tenet Healthcare Corporation will post 17.61 EPS for the current year.

Insider Buying and Selling

In other Tenet Healthcare news, Director J Robert Kerrey sold 5,638 shares of Tenet Healthcare stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total value of $983,943.76. Following the sale, the director owned 16,804 shares of the company’s stock, valued at $2,932,634.08. The trade was a 25.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Nadja West sold 3,000 shares of Tenet Healthcare stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total value of $532,050.00. Following the completion of the sale, the director directly owned 24,805 shares in the company, valued at approximately $4,399,166.75. The trade was a 10.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.97% of the stock is currently owned by insiders.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.